Global X S&P Biotech ETF
What CURE does
The Global X S&P Biotech ETF (CURE) allows investors to tap into the dynamic world of biotechnology by investing in a diverse range of biotech companies. This ETF focuses on firms that are involved in the development of new drugs and medical treatments, offering exposure to cutting-edge innovations in healthcare. With a management fee of 0.45%, CURE provides a straightforward way to invest in the biotech sector, aiming to capture growth from advancements in medical technology and pharmaceuticals. This makes it an attractive option for those interested in the potential of the biotech industry without having to pick individual stocks.
Management Fee
0.45%
Distribution Yield
0.00%
Fund Under Management
$41M
+3.99M
Monthly Liquidity
5.86%
Spread
0.47%
Last Price
...
Product Type
ETFMonthly fund flows
12-Month Flow
$-4.83M
Trading Activity
Transacted Value
$2M
Volume
39,960
Number of Trades
563
Monthly Liquidity
5.86%
Performance
1 Month
10.71%
1 Year
22.30%
3 Year
15.91%
5 Year
0.90%
Total Return
Share Price Chart
Related ETFs
Resources
Should you buy Global X S&P Biotech ETF right now?
While CURE looks interesting right now, our experts have just put together a full report on the ultimate ASX investment portfolio - designed for growth and passive income.
Join the Rask weekly investment newsletter to get the names, right now